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ORIGINAL ARTICLE
Feasibility and effects of a decision aid about fertility preservation
Mirjam M. Garvelinka, Moniek M. ter Kuilea, Leoni A. Louwea, Carina G.J.M. Hildersb and
Anne M. Stiggelboutc
aDepartment of Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands; bDepartment of Gynaecology, Reinier de
Graaf Hospital, Delft, The Netherlands; cDepartment of Medical Decision Making, Leiden University Medical Centre, Leiden,
The Netherlands
ABSTRACT
This paper reports on the feasibility and preliminary effects of a decision aid (DA) about
female fertility preservation (FP). We conducted a pilot multicentre randomized controlled trial
of women with breast cancer aged 18–40 who were randomized to brochures or the DA. Over
18 months, 62 women were eligible, of which 42 were invited by their healthcare provider
(74%) to participate in the study. A total of 36 women signed up for participation and 26
(72%) were randomized to brochures (n¼ 13) or the DA (n¼ 13). In both groups, many
women (87%) read the brochures and eight women used all available brochures. In the inter-
vention group, 7/13 women logged in to the DA. Women who received brochures had slightly
less decisional conflict, whereas knowledge improved in both groups. Our results indicate that
both brochures about FP and a detailed DA have beneficial effects with regard to knowledge,
but the DA seemed to introduce slightly more decisional conflict (DC) than the brochures.
Although we encountered challenges with recruitment, our design and measurements seem
feasible and the effects of the information materials seem promising, hence justifying conduct-
ing a larger study.
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Introduction
Infertility or concerns about (in)fertility due to cancer
treatment have a negative influence on quality of life
(Partridge et al., 2004; Wenzel, DeAlba, et al., 2005).
Therefore, interest in possibilities for fertility preserva-
tion (FP) has increased. At this moment, options to try
to preserve fertility prior to oncology treatment are
the cryopreservation of in vitro fertilized embryos,
oocytes, and ovarian tissue, and suppression of the
ovaries. The success rates of these options range from
5 to 25% (Garvelink, ter Kuile, Hilders, Stiggelbout, &
Louwe, 2013). Despite an increasing number of studies
and guidelines demonstrating the need for discussion
of FP issues with cancer patients, information provision
about treatment-induced infertility and FP techniques
and referral for FP are still not sufficient and often pro-
vided too late (Dunn & Steginga, 2000; Jenninga,
Hilders, Louwe, & Peters, 2008; Nakayama et al., 2009;
Quinn et al., 2007; Rosen, Rodriguez-Wallberg, &
Rosenzweig, 2009; Thewes et al., 2005; Tschudin &
Bitzer, 2009).
Adequate information fulfils psychosocial needs
(Peate, Meiser, Hickey, & Friedlander, 2009), increases
coping with cancer (Ream & Richardson, 1996) and
enables informed decision making (DM) (Mersereau
et al., 2013). An informed decision is a decision based
on relevant, best available evidence and reflects a
patient’s values (Michie, Dormandy, & Marteau, 2002).
Informed DM is especially important in deciding on
treatments with possible long term consequences for
quality of life such as FP options.
To support informed DM, and improve information
provision about FP, a web-based Decision Aid (DA)
was developed in Dutch (Garvelink, Ter Kuile, Fischer,
et al., 2013). With the availability of this DA, every
patient who is eligible for counselling about FP can
obtain optimal information about FP at any time and
in any location.
We sought to pilot test the feasibility and effects of
the detailed DA compared to brochures about FP on
decisional conflict (DC), knowledge, regret, and repro-
ductive concerns. To this end, we conducted a
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multicentre randomized controlled trial with young
women with breast cancer in oncology and gynaecol-
ogy departments of medical centres in the
Netherlands.
Materials and methods
Study design
A pilot multicentre randomized controlled trial, with
randomization between informational brochures or a
DA about FP, stratified by medical centre. We used a
block randomization scheme with variable blocks sizes,
developed by the department of medical statistics of
the Leiden University Medical Centre (LUMC). The
study was approved by the Medical Ethics Committee
of LUMC (Dutch trial register NL32155.058.11).
Intervention and control
The DA is a web-based tool consisting of five chapters
(26 separate web pages) with textual information, and
a values clarification exercise to weigh pros and cons
of the FP options (nine separate web pages; www.
borstkankerenkinderwens.nl). The DA was developed
using a systematic, user-centred process with involve-
ment of patients and clinicians (Garvelink, Ter Kuile,
Fischer, et al., 2013). The paper-based brochures (con-
trol) and web-based DA (intervention) contained the
same information about FP options and about cancer
treatments and their impact on fertility, but the DA
additionally contained background information about
normal fertility, an explicit values clarification exercise,
and a question prompt sheet (Garvelink, Ter Kuile,
Fischer, et al., 2013). The DA contained all information
in one source, whereas the brochures contained infor-
mation on one FP-option per brochure. There were in
total four different brochures: a general brochure
about breast cancer treatment and FP, and a separate
brochure for each of the FP-options (cryopreservation
of ovarian tissue, embryos and oocytes). Both the bro-
chures and the DA fulfilled the six minimal qualifying
criteria for DAs (Elwyn et al., 2009; Joseph-Williams
et al., 2014).
Participants, recruitment strategy and setting
Eligible participants were female breast cancer patients
between 18 and 40 years old, who were likely to
receive chemotherapy, and who were eligible for FP.
Women had to speak Dutch and have access to the
Internet. Participants were invited to take part in the
study either by their surgeon, oncologist or breast
cancer nurse soon after diagnosis but before they
were referred for counselling about FP; or by their spe-
cialised gynaecologist or fertility specialist, after (refer-
ral for) a first counselling consultation about FP (but
before their decision to undergo FP or not had been
made).
Eligible women received an envelope containing an
invitation letter, a study brochure, and a general bro-
chure about breast cancer and fertility. Women either
enrolled themselves in the study, or let their breast
cancer nurse/clinician do it. After signing up, they
received the baseline questionnaire by e-mail. All
women gave informed consent. Randomization took
place after completion of the baseline questionnaire,
with a link to the web-based DA or to a digital version
of the brochures. All brochures were also publicly
available, since we did not want to withhold relevant
information from patients who did not participate in
this study. Most participating medical centres handed
out the brochures to all eligible patients, including
those in the DA group. Respondents received 10 euros
for completing three questionnaires.
Oncology departments of 26 medical centres had
agreed to participate in the study, of which 13 actually
recruited women. In addition, in three medical centres
specialized gynaecologists or fertility specialists
recruited women. Data were collected between June
2011 and December 2012.
Measurements
(i) Feasibility outcomes
Feasibility of the recruitment was measured by the pro-
portion of participants eligible, invited and recruited
after 16 months and the proportion of completed
questionnaires after 18 months. For this we invited
healthcare professionals in participating centres to
complete a short questionnaire about their recruit-
ment in the first 16 months.
(ii) Use of information
Individual website statistics were used to measure
time spent on each page and on the total DA, and
number and types of pages viewed during the visit. In
addition, women were asked to indicate for each bro-
chure whether they had read it and if so how thor-
oughly they had read it.
(iii) Effectiveness of the DA and other measures
Secondary outcomes were assessed using an online
self-report questionnaire at baseline (T0), six weeks
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after T0, when a decision was expected to be made
(T1), and six months after T0, when we expected
women to be able to look back at the decision (T2).
Socio-demographic and medical characteristics were
measured at baseline, with possibility to change them
in follow-up questionnaires.
FP preference was measured with a single question
at T0/T1/T2; the actual decision was measured at
T1/T2.
Decisional conflict was measured at T1/T2 with the
Decisional Conflict Scale (DCS; including its subscales
DM uncertainty, informed DM, values clarity, DM sup-
port, effective DM), validated for a Dutch population
(Koedoot et al., 2001; O’Connor, 1995). The 16 items
are measured on a 5-point Likert scale ranging from 0
(totally disagree) to 4 (totally agree). Total scores range
from 0-100. A higher score indicates more DC.
Cronbach’s a (T1) was 0.82 for the total DCS (T1; sub-
scales ranged from a¼ 0.42–0.69).
Knowledge about FP was measured at T0/T1/T2 with
10 statements, with answering categories “true”,
“false”, or “do not know” (e.g. “Cryopreservation of
embryos is possible until the age of 40 [true]”). Total
scores range from 0 to 10.
Reproductive concerns were measured at T0/T1/T2
with a Dutch version of the Reproductive Concerns
Scale (RCS) (Garvelink, Ter Kuile, Louwe, Hilders, &
Stiggelbout, 2015; Wenzel, Berkowitz, Robinson,
Bernstein, & Goldstein, 1992; Wenzel, Dogan-Ates,
et al., 2005). The Dutch version of the scale consists of
11 of the 14 original items, measured on a 5-point
scale ranging from 0 (not at all) to 4 (very much).
Total scores range from 0 to 44. Cronbach’s a (T0) was
0.83.
Decisional regret related to FP was measured at T1/
T2 with a 5-item decision regret scale (Brehaut et al.,
2003). Items were measured on a 5-point Likert scale
ranging from 0 (totally disagree) to 4 (totally agree).
Total scores range from 0 to 20. Cronbach’s a of the
decisional regret scale (T1) was 0.61. At baseline we
measured anticipated regret, with two items asking
after the extent to which women expected to have
regret if they did not pursue FP now, when they
would appear to be infertile after cancer treatment
and if they did pursue FP now, when they would
appear to still be fertile after cancer (van Dijk, van
Roosmalen, Otten, & Stalmeier, 2008).
Analyses
Data were analysed descriptively. Due to the small
number of participants we used nonparametric tests
for all statistical analyses. Data analyses were done
with SPSS 20.0 for Windows (IBM Corp., Armonk, NY).
To perform analyses on as many participants as pos-
sible, missing data on outcome measures at T1 and T2
were handled using Multiple Imputation (Barnes,
Lindborg, & Seaman, 2006; Graham, 2009). We used
data on randomization group and all continuous sec-
ondary outcomes as predictors in the imputation
model. Data were imputed five times, and combined
using Rubin’s (1987) rules for multiple imputation.
Results
Participants
Thirty-six women were enrolled into the study, of
which six did not start the baseline questionnaire, two
did not give informed consent and two did not com-
plete the baseline questionnaire and could therefore
not be randomized. Thus, 26 women (72%) completed
the baseline questionnaire and were randomized to
brochures (n¼ 13) or the DA (n¼ 13) (Figure 1). In
both groups 12 women (92%) completed the T1 ques-
tionnaire, and the T2 questionnaire was completed by
12 (92%) women in the control group (brochures) and
11 (85%) randomised to the DA (Figure 1). Women
who completed all questionnaires were somewhat
higher educated than women who missed measure-
ments. Otherwise, we did not find differences between
them. Data on relevant outcome measures were there-
fore imputed for missing data at T1 (n¼ 5) and T2
(n¼ 5).
Feasibility of recruitment
Nine centres responded (64%) and reported 62 eligible
women in the first 16 months of recruitment. Of these,
16 women had not been invited (because it was for-
gotten, or they had already had a consultation with a
fertility specialist, did not visit their breast cancer
nurse, had to undergo neo-adjuvant chemotherapy,
had no desire for children, or they were invited for too
many studies already). Twenty-four women were
invited but did not want to participate (because they
had no desire for children or had had previous preg-
nancies/children, had metastasized cancer, or were
preoccupied with the cancer). Twenty-two women
agreed to participate. Of these, 19 women enrolled
into the study (Figure 1).
Two women were invited by medical centres that
did not complete the above mentioned questionnaire,
so we do not know their relative proportion of the
total number of eligible women in these centres. In
addition, for the last two months of the study, and for
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those who were recruited by a gynaecologist or fertil-
ity specialist, we do not have as detailed recruitment
information as for those women who were recruited
by their oncology department in the first 16 months
of the study. Moreover, three additional women
signed up in the last two months, and 12 women
were invited via their gynaecology department (Figure
1).
Use of the information
Twenty women reported to have used the general
brochure about FP (87%; three missing) (Table 1).
Eight women used all available brochures. Women,
who read the brochures, read the brochures
completely. Of the 13 women who were randomized
to the DA group, seven (54%) logged in to the DA, of
whom six used the Values Clarification Exercise (VCE).
The mean time spent on the DA was 29minutes
(range: 1–74). Women viewed on average 15 of the 26
informational pages (range 0–53; some pages were
viewed more than once), and 9 of the 9 VCE-pages
(range: 0–21).
Secondary outcomes
At baseline, there were no differences with regard to
socio-demographic and medical characteristics
between the two study groups (Table 2). With regard
to outcome measures, women who received brochures
had a significantly lower perception (p¼ 0.046) of their
risk of losing fertility (M¼ 6.7) compared to women
who received the DA (M¼ 8.2), but this was not corre-
lated to other outcome measures. Otherwise there
were no differences.
Preferences and decision making
At baseline 16 women (62%) had a preference regard-
ing FP, but none had decided to undertake it. At T1,
21 women (88%) had a preference, 23 women (96%)
had made a decision (some had no choice due to
characteristics of the situation, and hence no real pref-
erence). At T2 all women (n¼ 23) made a decision
about FP: 10 women had chosen not to pursue FP
(43%), 11 had cryopreserved embryos (48%), one had
cryopreserved oocytes (4%), and one both oocytes and
embryos (4%). There were no differences in choices
Table 1. Use of information materials by the study
participants.
Brochure
group (n¼ 13a)
Decision aid
group (n¼ 13a)
Brochures read, n(%)
General brochure 10 (83) 10 (91)
Cryopreservation of embryos 10 (83) 8 (73)
Cryopreservation of ovarian tissue 7 (58) 4 (36)
Cryopreservation of oocytesb 6 (50) 3 (27)
All brochures 5 (42) 3 (27)
Other – –
Use of the DA, n (%) – 7 (54)
Textual information read – 7 (100)
VCEþ textual information used – 6 (86)
Websiteþ brochures used – 6 (86)
Counselling consultation n (%)
Fertility/gynaecology 11 (92) 12 (100)
Oncology 4 (33) 5 (42)
aDue to missing values, all percentages are calculated on a total of resp.
12 and 11 women in the brochure and DA groups.
bBecame available halfway the study period.
DA: decision aid; VCE: values clarification exercise.
Figure 1. Flow chart of recruitment and in- and exclusion of patients.
HUMAN FERTILITY 107
D
ow
nl
oa
de
d 
by
 [R
ad
bo
ud
 U
niv
ers
ite
it N
ijm
eg
en
] a
t 0
0:0
5 2
4 O
cto
be
r 2
01
7 
between the two study groups. Five women (22%)
mentioned not to have had a choice about FP.
Decisional conflict
Women who received the brochures scored signifi-
cantly lower on the effective DM subscale of the DCS
(indicating they made an informed, values based deci-
sion that is likely to be implemented) than women
who received the DA in addition to brochures. Total
DC was not significantly different. At T2 there was a
weak trend towards more total DC, and effective DM
in the DA group.
Knowledge
In terms of knowledge, significant differences were
found between baseline and T1 (DM¼ 1.35 out of 10),
and baseline and T2 (DM¼ 1.25, p¼ 0.004; 0.56),
indicating a relative increase of 22%. There were no
differences between intervention and control groups.
Regret and reproductive concerns
There were no statistically significant differences in
anticipated regret between measurement moments,
nor were there differences in regret between groups.
Both groups showed a trend for a minor increase in
regret between measurements made at T1 and T2
(DM¼ 4.9; p¼ 0.15; d¼0.29). At baseline, both
groups anticipated more regret when not undergoing
FP and becoming infertile, than when undergoing it
and remaining fertile (indicating that it had not been
necessary to pursue FP). There were no differences
between groups or measurement moments with
regard to reproductive concerns (Table 3).
Differences between women recruited via
gynaecology versus oncology
Women who were recruited via their gynaecologist
were recruited at a different moment in their trajectory
between diagnosis and start of the oncology treat-
ment, and may have received more information on FP
than those recruited by their oncologist. Therefore, we
conducted additional analyses to see whether this
route influenced the outcomes. Of the women who
were invited through their gynaecologist, DA use was
higher compared to that of women recruited via their
oncologist (80.0% versus 37.5%). Additionally, they had
slightly higher baseline knowledge than those
recruited by their oncologist (6.4 versus 5.0 out of 10),
as well as at T1 (7.8 versus 6.4 out of 10) and T2 (7.4
versus 6.2 out of 10), but the increase in knowledge
was similar between the two groups (1.0 versus 1.2
out of 10). Otherwise there were no differences with
regard to the outcomes.
Discussion
This study informed the feasibility, and pilot tested the
effects of a DA about FP for women with breast cancer
in oncologic and gynaecologic practice. Although the
intended outcomes were feasible to be measured with
digital questionnaires, and the DA was feasible to pro-
vide to the respondents, we encountered challenges
with recruitment of participants and subsequent par-
ticipation rates. We have made an attempt to assess
effectiveness of the DA compared to brochures about
FP. Despite our small sample size, the study showed
some remarkable findings. Women in our sample
experienced relatively low levels of DC, with the sug-
gestion of a slightly lower score on the effective DM
subscale of the DCS at T1, and higher total levels of
DC at T2, in women who received the DA, compared
to women who received brochures (Cohen’s d¼ 0.34).
The results of our study lead us to make five
observations.
First, recruitment of women for a study to evaluate
information provision, between diagnosis and start of
the oncologic treatment, was difficult. Fewer women
than anticipated were eligible for the study (a majority
of newly diagnosed women had complete families or
no desire for children), and the combination of the dif-
ficult timing in which women had to be invited, the
increasing number of studies for breast cancer
patients, and the burden of a cancer diagnosis made
Table 2. Socio-demographic and medical characteristics of
the participants.
Brochure group
(n¼ 13)
Decision aid
group (n¼ 13)
Age, mean (range) 32.9 (28–39) 35.8 (30–40)
Male partner, n (%) 12/13 (92) 12/13 (92)
Of whom cohabiting n (%) 10/12 (83) 12/12 (100)
Parity 0<, n (%) 7/13 (54) 7/13 (54)
Desire for children, yes (%) 13/13 (100) 13/13 (100)
Religious, no (%) 7/13 (54) 8/13 (62)
Educational level
Low 1/13 (7) –
Middle 3/13 (23) 3/13 (23)
High 9/13 (69) 10/13 (77)
Self-reported breast cancer treatmenta
Surgery 12/12 (100) 11/11 (100)
Chemotherapy 12/12 (100) 8/11 (73)
Radiotherapy 7/12 (58) 10/11 (91)
Endocrine therapy 7/12 (58) 10/11 (91)
Immunotherapy 3/12 (25) 1/11 (9)
aDue to missing values, percentages are calculated on a total of resp. 12
and 11 women in the brochure and Decision aid groups.
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recruiters hesitant to invite them or discouraged wom-
en’s participation. Moreover, the fact that the bro-
chures were already publicly available made
participation no longer necessary to obtain the infor-
mation about FP.
Second, in our study, several health professionals
could invite women, but the actual enrolment into the
study was done by the researcher. It might help
recruitment to future studies to appoint local cham-
pions who are, and feel, responsible for inclusion of
participants in their medical centre (Rendell, Merritt, &
Geddes, 2007). Additionally, women were often given
the materials to take home so that they could enrol
themselves into the study, instead of directly being
enrolled by their health professional. This could have
been a threshold for their enrolment. In future
research, it would be interesting to engage patients in
designing the most appropriate procedure for recruit-
ment in a period with such a difficult timing
(Fleurence et al., 2014).
Third, the slightly more favourable outcomes with
regard to DC in the brochure group compared to the
DA group is in contrast to what we expected based
on other DA evaluations (Stacey et al., 2014). Reasons
for this may be related to the type and moment of
the decision, or the design of the DA:
1. The decision about FP is a different type of deci-
sion when compared to screening- or treatment
decisions. The decision about FP has to be made
in a difficult (and short) time frame with compet-
ing demands from decisions related to surviving
the cancer (Garvelink et al., 2015; Lee et al., 2011).
Explicit confrontation through a DA may therefore
increase DC;
2. Our data indicated that a majority of the women
had strong baseline preferences and may have
made their decision before seeing the DA, or did
not experience a choice because the preferred FP
option was determined by their possibilities in
combination with the highest possible success
rates (Garvelink et al., 2015). Seeing the DA with
all FP options when a decision has already been
made, or when there is no choice may have (re)in-
itiated the DM process and consequent uncer-
tainty, which is likely to lead to more DC; and
Table 3. Decision making processes and outcomes for the study participants (n¼ 26).
Brochures (n¼ 13) BrochuresþDA (n¼ 13)
Mean ± SD Mdn Mean ± SD Mdn p value/z value/Cohen’s d
Knowledge
T0 5.7 ± 1.8 5.7 5.5 ± 1.8 5 p¼ 0.772/z¼0.289/d¼0.06
T1 6.9 ± 1.5 6.7 7.0 ± 1.6 7 p¼ 0.668/z¼0.576/d¼0.12
T2 6.6 ± 1.2 6.6 7.1 ± 1.4 7 p¼ 0.264/z¼1.1448/d¼0.24
Total decisional conflict scale (DCS)
T1 15.9 ± 8.9 17.8 21.7 ± 14.8 23.4 p¼ 0.256/z¼1.137/d¼0.24
T2 14.2 ± 10.6 14.1 23.7 ± 17.9 28.1 p¼ 0.115/z¼1.585/d¼0.34
Values clarity (DCS)
T1 14.3 ± 15.4 8.3 24.1 ± 16.5 25 p¼ 0.105/z¼1.625/d¼0.32
T2 15.3 ± 13.5 16.6 29.5 ± 27.2 25 p¼ 0.147/z¼1.47/d¼0.25
Decision making support (DCS)
T1 16.9 ± 16.0 15.7 22.2 ± 15.8 25 p¼ 0. 465/z¼0.736/d¼0.14
T2 12.6 ± 13.4 8.3 21.3 ± 14.7 25 p¼ 0.145/z¼1.468/d¼0.25
Effective decision making (DCS)
T1 5.4 ± 7.6 0.0 16.1 ± 12.5 18.7 p¼ 0.024/z¼2.262/d¼0.44
T2 10.7 ± 11.9 6.3 18.7 ± 16.9 13.8 p¼ 0.181/z¼1.342/d¼0.22
Informed decision making (DCS)
T1 30.3 ± 20.8 33.3 25.2 ± 22.8 25 p¼ 0.531/z¼0.629/d¼0.12
T2 21.3 ± 18.8 25.0 29.3 ± 28.8 25 p¼ 0.616/z¼0.504/d¼0.08
Decision making uncertainty (DCS)
T1 16.9 ± 16.3 16.6 23.8 ± 21.2 25 p¼ 0.307/z¼1.022/d¼0.20
T2 11.9 ± 10.0 13.5 20.8 ± 13.8 25 p¼ 0.07/z¼1.792/d¼0.30
Decisional regret
T1 13.9 ± 11.3 10.6 18.6 ± 16.3 15 p¼ 0.438/z¼0.783/d¼ 0.016
T2 17.6 ± 11.2 18.6 24.7 ± 20.6 22.5 p¼ 0.499/z¼0.068/d¼ 0.014
Anticipated regret (T0)
From not undergoing FP 1.85 ± 1.2 2.0 2.23 ± 0.93 2 p¼ 0.461/z¼0.738/d¼0.15
From undergoing FP 0.15 ± 0.38 0.0 0.23 ± 0.44 0 p¼ 0.626/z¼0.488/d¼0.10
Reproductive concerns
T0 13.1 ± 7.3 11.0 13.4 ± 7.9 15 p¼ 0.898/z¼0.128/d¼ 0.13
T1 12.3 ± 7.1 12.5 11.1 ± 4.8 12.8 p¼ 0.895/z¼0.132/d¼ 0.11
T2 10.7 ± 4.9 9.0 13.4 ± 6.4 15 p¼ 0.079/z¼1.759/d¼ 0.62
Minimum–maximum scores: knowledge 0–10; total Decisional conflict scale (DCS), including subscales 0–100; decisional regret 0–100; anticipated regret
0–5; reproductive concerns 0–40.
DA: decision aid; FP: fertility preservation.
HUMAN FERTILITY 109
D
ow
nl
oa
de
d 
by
 [R
ad
bo
ud
 U
niv
ers
ite
it N
ijm
eg
en
] a
t 0
0:0
5 2
4 O
cto
be
r 2
01
7 
3. The design and content of our DA may have sug-
gested a difficult decision for the women [in an
implicitly normative way (Molewijk, Stiggelbout,
Otten, Dupuis, & Kievit, 2003)]. Indeed, we only
found significant differences in DC at T1, and not
on the longer term. Moreover, all FP options are
mentioned in the DA, which will not be optional
for all women. For some women the availability of
information about irrelevant options might be
confusing, while others want to see as much infor-
mation as possible (Molewijk et al., 2003;
Stiggelbout et al., 2008). Importantly, a slight
increase in DC is not disadvantageous (Knops
et al., 2013; Nelson, Han, Fagerlin, Stefanek, &
Ubel, 2007), especially when the level of conflict is
not above the threshold for elevated DC (as was
the case) (O'Connor, 1995). This may for example
indicate that women are strongly involved in the
decision (Nelson et al., 2007).
Fourth, both information sources led to a signifi-
cant increase in knowledge between baseline and fol-
low-up, comparable to other studies (Peate et al.,
2012). Unlike other studies (Peate et al., 2012; Stacey
et al., 2014) the knowledge scores in our study did
not differ between groups. However, the information
in the brochures and DA was highly overlapping, and
women in both randomization groups read the
brochures.
Fifth, when we compared our results with regard to
knowledge and DC to previous data of a historical
group of women who only received counselling con-
sultation, both brochures and our DA had more
favourable scores on DC and knowledge than in
women who received counselling only (Garvelink, Ter
Kuile, Louwe, Hilders, & Stiggelbout, 2013; Peate et al.,
2012). Therefore, the benefit of any additional informa-
tion with regard to knowledge and feeling supported
in DM about FP is clear (Garvelink, Ter Kuile, Louwe,
et al., 2013). However, besides additional written infor-
mation, referral to a fertility expert for counselling
about FP is still of utmost importance (Kim et al.,
2013). Indeed, the information in the DA could be a
good addition to information received by the gynae-
cologist, as suggested by our finding that women who
were recruited through their gynaecologist (and hence
had already received some information on FP) still had
similar relative increases in knowledge between meas-
urement moments, when compared to women
recruited by their oncologist.
Some important limitations must be taken into
consideration in interpreting these results. Our sam-
ple size is very small. Therefore, results are
preliminary and based on non-parametric tests only.
Recruitment was a huge problem in our study
which may be a challenge for future larger trials.
With the incidence for breast cancer in young
women in the Netherlands being almost 1000
women a year, we expected to be able to include
enough participants to find small effects in DC
(Cohen’s d¼ 0.2; b¼ 0.2; a¼ 0.05) between random-
ization groups within 18 months. After 18 months
we stopped randomization as planned, for reasons
of funding. Additionally, the brochures that we used
as comparison, could be considered simple DAs
since they fulfilled all minimum criteria for DAs, so
a priori changes of finding significant differences
between the groups were low.
Future research should take into account the afore
mentioned challenges in order to provide more defini-
tive effects of the DA and to be able to formulate a
final recommendation for their use in practice.
However, in the meantime, it is of utmost importance
that women are offered timely information about FP
in addition to counselling and our results suggest that
the DA as well as brochures improved knowledge and
had no disadvantageous effects. Therefore, we recom-
mend that both can be used to inform future patients,
until proven otherwise. However, since use of the DA
slightly increased decisional conflict, additional assist-
ance in DM (during counselling consultations) should
be available.
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